Skip to main content
RXRX logo

Recursion Pharmaceuticals, Inc.

RXRXNASDAQHealthcareBiotechnology

$4.05Today:- (-)1Y −37.52%

As of Oct 27, 2026 close

Market cap
$2.16B
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$2.77$6.70
Volume (live)
-
Avg. volume (3M)
29.32M

Recursion Pharmaceuticals (RXRX) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Recursion Pharmaceuticals reported total assets of $1.47B and total liabilities of $343.26M. Shareholders' equity was $1.13B, up 9.3% from $1.03B a year earlier. Total debt stood at $18.66M against $743.29M in cash and short-term investments, a net cash position of $724.64M. That puts debt-to-equity at 0.02, compared with 0.03 a year earlier.

Recursion Pharmaceuticals Balance Sheet Analysis

Values in billions USD

Scroll to see more
Balance sheet showing assets, liabilities, and shareholders' equity for Recursion Pharmaceuticals, Inc. (RXRX) - Annual data in billions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Current Assets
Cash and Cash Equivalents0.740.590.390.550.290.260.07
Short-Term Investments0.000.000.000.000.230.000.00
Cash & Short-Term Investments0.740.590.390.550.520.260.07
Accounts Receivable0.020.050.000.000.000.000.00
Inventory0.000.000.000.000.000.000.00
Other Current Assets0.030.040.040.020.010.000.01
Total Current Assets0.810.710.440.570.530.270.08
Non-Current Assets
Property, Plant & Equipment (Net)0.170.230.120.120.060.030.02
Long-Term Investments0.000.010.000.000.000.000.00
Goodwill0.160.150.050.000.000.000.00
Intangible Assets0.310.340.040.000.000.000.00
Other Non-Current Assets0.020.010.010.010.010.000.00
Total Non-Current Assets0.660.730.220.130.080.030.03
Total Assets1.471.450.650.700.610.300.10
Current Liabilities
Accounts Payable0.020.020.000.000.000.000.00
Short-Term Debt0.010.010.000.000.000.000.00
Current Portion of Long-Term Debt-0.000.000.000.000.00-
Accrued Liabilities0.040.030.020.030.020.01-
Deferred Revenue0.040.060.040.060.010.010.00
Other Current Liabilities0.070.080.050.000.000.010.00
Total Current Liabilities0.150.190.090.100.050.020.01
Non-Current Liabilities
Long-Term Debt0.010.020.000.000.000.010.02
Deferred Tax Liabilities0.020.020.000.000.000.000.00
Other Non-Current Liabilities0.000.000.000.070.020.450.20
Total Non-Current Liabilities0.200.230.100.120.020.480.22
Total Liabilities0.340.410.190.220.070.500.23
Stockholders' Equity
Common Stock0.000.000.000.000.000.000.00
Retained Earnings-2.08-1.43-0.97-0.64-0.40-0.21-0.13
Accumulated Other Comprehensive Income0.04-0.010.000.000.000.000.00
Additional Paid-in Capital3.172.471.431.130.940.010.00
Shares Outstanding0.530.400.230.190.17--
Total Stockholders' Equity1.131.030.460.490.54-0.21-0.12
Total Liabilities & Equity1.471.450.650.700.610.300.10

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Recursion Pharmaceuticals Balance Sheet

How much debt does Recursion Pharmaceuticals have?

Recursion Pharmaceuticals had total debt of $18.66M as of Dec 31, 2025, against $743.29M in cash and short-term investments. Its debt-to-equity ratio was 0.02. Total debt was $27.45M a year earlier.

What are Recursion Pharmaceuticals's total assets?

Recursion Pharmaceuticals reported total assets of $1.47B as of Dec 31, 2025, up 1.8% from $1.45B a year earlier. Total liabilities were $343.26M.

What is Recursion Pharmaceuticals's shareholders' equity?

Recursion Pharmaceuticals's shareholders' equity was $1.13B as of Dec 31, 2025, or about $2.14 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition